Log In

EDRN Catalog and Archive Service

SELDI EVMS UnProcessed Data

Dataset Abstract:

Unprocessed SELDI bioprocessor output from EVMS (Eastern Virginia Medical School), EDRN Site 92. Each spectra was calibrated and normalized to an external coefficient of 0.2 using Ciphergen's "Peaks" software. Raw time of flight values were then exported as combined spread sheets representing many individual spectra produced from serum samples in each study. These files are comma delimited (csv).

The following additional information has been defined for this dataset. The information has been provided by the Principal Investigator or staff from his or her laboratory.

SELDI Validation Study Phase II
SELDI EVMS UnProcessed Data
John Semmes
University of Washington (Associate Member)
Dale McLerran
Prostate and Urologic
Specific Aim Phase II - The overall goal of Phase II is to develop and evaluate an algorithm for classifying cases and controls using protein profiles produced from SELDI-TOF-MS using serum collected from prostate cancer cases and non-cancer controls. Objective 1 - Identification of biorepositories Objective 2 - Generate protein profiles Objective 3 - Construction of classifiers and development of algorithm. Objective 4 – Validate the classifier constructed in Objective 3. If Objective 3, Aim 1, is successfully met
The EDRN-Prostate-SELDI Investigational Collaboration (EPSIC) will implement a process to synchronize SELDI output at the seven participating institutions using a single source of pooled normal sera (QC). The target was to recruit 100 healthy males and 100 healthy females to donate two tubes of blood. Pregnant women and subjects less than 110 pounds were excluded from the blood collection. An IRB protocol was submitted two months in advance of the project. After IRB approval, fliers were generated and posted at many locations (e.g., EVMS, hospitals, doctor's offices). The blood was collected on November 6, 2002 from 7:30 am to 2:00 pm. A total of 360 healthy people (154 male and 206 female) donated two tubes of blood each to make quality control (QC) serum.
It is then the goal of this collaborative project - EDRN-Prostate-SELDI Investigational Collaboration (EPSIC) - to use state-of-the-art protein profiling technology to develop and validate such screening methods
Data and information released from the National Cancer Institute (NCI) are provided on an "AS IS" basis, without warranty of any kind, including without limitation the warranties of merchantability, fitness for a particular purpose and non-infringement. Availability of this data and information does not constitute scientific publication. Data and/or information may contain errors or be incomplete. NCI and its employees make no representation or warranty, express or implied, including without limitation any warranties of merchantability or fitness for a particular purpose or warranties as to the identity or ownership of data or information, the quality, accuracy or completeness of data or information, or that the use of such data or information will not infringe any patent, intellectual property or proprietary rights of any party. NCI shall not be liable for any claim for any loss, harm, illness or other damage or injury arising from access to or use of data or information, including without limitation any direct, indirect, incidental, exemplary, special or consequential damages, even if advised of the possibility of such damages. In accordance with scientific standards, appropriate acknowledgment of NCI should be made in any publications or other disclosures concerning data or information made available by NCI.